Viewpoint | Published:

Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 180181 (2006) | Download Citation


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454–1457

  2. 2.

    (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245–262

  3. 3.

    et al. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115: 94–101

  4. 4.

    et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238–4245

  5. 5.

    et al. (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646–6656

  6. 6.

    et al. (2006) PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91: 213–220

  7. 7.

    et al. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373–6379

  8. 8.

    et al. (2005) High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90: 5265–5269

  9. 9.

    et al. (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399–5404

  10. 10.

    et al. Inhibitors of raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res, in press

Download references

Author information


  1. L Groussin is a visiting post-doctoral fellow (from Groupe Hospitalier Cochin, Paris, France) and JA Fagin is a Professor of Medicine in the Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

    • Lionel Groussin
    •  & James A Fagin


  1. Search for Lionel Groussin in:

  2. Search for James A Fagin in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to James A Fagin.

About this article

Publication history





Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing